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Parasitized red blood cells (RBCs) from children suffering from
severe malaria often adhere to complement receptor 1 (CR1) on
uninfected RBCs to form clumps of cells known as ‘‘rosettes.’’
Despite a well documented association between rosetting and
severe malaria, it is controversial whether rosetting is a cause or a
correlate of parasite virulence. CR1-deficient RBC show greatly
reduced rosetting; therefore, we hypothesized that, if rosetting is
a direct cause of malaria pathology, CR1-deficient individuals
should be protected against severe disease. In this study, we show
that RBC CR1 deficiency occurs in up to 80% of healthy individuals
from the malaria-endemic regions of Papua New Guinea. This RBC
CR1 deficiency is associated with polymorphisms in the CR1 gene
and, unexpectedly, with-thalassemia, a common genetic disorder
in Melanesian populations. Analysis of a case-control study dem-
onstrated that the CR1 polymorphisms and -thalassemia inde-
pendently confer protection against severe malaria. We have
therefore identified CR1 as a new malaria resistance gene and
provided compelling evidence that rosetting is an important par-
asite virulence phenotype that should be a target for drug and
vaccine development.
Severe malaria remains one of the largest causes of childhoodmortality in the world. The number of deaths is high at1–2
million per year; however, this number represents a small
fraction of the total number of clinical malaria episodes that
occur worldwide, estimated to be 400–900 million (1). Much
work has been done to determine the factors that lead to the
development of severe malaria, with parasite virulence pheno-
types and host genetic factors being two major foci of research.
One such Plasmodium falciparum virulence phenotype is roset-
ting, an adhesion property in which parasitized red blood cells
(RBCs) bind to unparasitized RBCs to form clumps of cells (2).
Rosetting is thought to contribute to malaria pathology by
causing microvascular obstruction and impaired tissue perfusion
(3, 4). Rosetting has been associated with severe malaria in many
studies in Africa (e.g., refs. 5–7), although no association with
severe disease was seen in Southeast Asia (8) or Papua New
Guinea (PNG) (9). This inconsistency in the association of
rosetting with severe disease has led some investigators to
question the role of rosetting in malaria pathogenesis (10).
Rosetting is mediated by the parasite ligand PfEMP1 on the
surface of infected RBCs (11, 12), binding to a variety of
uninfected RBC receptors, including complement receptor 1
(CR1) (11, 13). CR1 is an immune-regulatory protein found on
RBCs and a variety of leukocytes, and its functions include
control of complement activation and the clearance of immune
complexes (14). On RBCs, CR1 levels vary between individuals
in the range of 50–1,200 molecules per cell (15–21). In Cauca-
sians, RBC CR1 levels are genetically determined and are
associated with at least three single-nucleotide polymorphisms
(SNPs) in the CR1 gene (in exon 22, intron 27, and exon 33; ref.
22). These SNPs comprise high (H) and low (L) CR1 expression
haplotypes that are codominant and are associated with CR1
level on RBC, but not on other cell types, such as B cells and
macrophages (15). We have shown previously that CR1-deficient
RBCs from LL homozygotes with 200 CR1 molecules per cell
show greatly reduced rosetting with P. falciparum-infected RBCs
(ref. 11 and J.A.R., unpublished data). We reasoned that if
rosetting is important in malaria pathology, then CR1 deficiency
should protect against severe disease by reducing rosette-
mediated microvascular obstruction. CR1 deficiency is thought
to be rare in most populations; however, a review article (23)
stated that 28 of 67 Melanesians had CR1-deficient RBCs. No
experimental details were given, and no further information was
published to validate this claim. This tantalizing suggestion that
CR1 deficiency could be very common in Melanesians led us to
examine the prevalence and genetic basis of CR1 deficiency in
PNG and to determine whether RBC CR1 deficiency protects
against severe malaria.
Methods
Study Sites and Sample Collection. We collected fresh blood samples
into EDTA from healthy adult volunteers at two malaria-endemic
sites within PNG (New Ireland and Madang) and from Edinburgh,
United Kingdom. Informed consent was given by all donors after
the aims of the project were explained, and the PNG Medical
Research Advisory Committee approved all protocols. In Edin-
burgh and New Ireland the blood samples were analyzed fresh,
whereas in Madang, buffy coats were removed for DNA extraction
and the RBCs were fixed in 5% formaldehyde (24) before shipping
to the United Kingdom. Buffy-coat samples from the Eastern
Highlands Province (PNG) were kindly made available to us by the
PNG Institute of Medical Research and came from a village 2,000
m above sea level, where no regular malaria transmission exists.
New Ireland and Madang both have intense year-round malaria
transmission with a spleen enlargement rate of 70% (25, 26).
Determination of RBC CR1 Level. The mean RBC CR1 level on both
fresh and fixed blood samples was determined as described (24).
In brief, the CR1 level was determined by flow cytometry using
the anti-CR1 monoclonal antibody J3D3, with comparison to a
standard curve derived from a set of reference RBCs with known
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CR1 levels. The reference RBCs used to establish the assay had
their CR1 expression initially determined by the use of 125I-
labeled antibody and Scatchard analysis to determine the num-
ber of antigenic sites per cell, controlling for the number of
antibody-binding sites per CR1 molecule (24). We have shown
that fresh and fixed RBC samples are similar and that CR1 level
can be assessed accurately on fixed RBCs provided that the
reference RBCs used to generate the standard curve are fixed in
the same manner (24).
DNA Extraction and Genotyping. DNA was extracted from buffy
coats by using the Nucleon BACC I kit (Amersham Pharmacia
Life Science). Samples were genotyped for three SNPs in the
CR1 gene at nucleotide 3650 in exon 22, a HindIII restriction
fragment length polymorphism in intron 27, and at nucleotide
5507 in exon 33 by PCR and restriction digest as described (22).
-Thalassemia genotyping for the3.7 and4.2 deletions was
done by multiplex PCR according to the method of Chong et al.
(27). Southeast Asian ovalocytosis genotype was determined by
PCR as described (28). DNA samples for the case-control study
were as described (29, 30) and were amplified by primer-
extension preamplification (31) before CR1 genotyping.
-Thalassemia genotyping for the case-control study was carried
out by Southern blotting (29).
Determination of Glucose-6-phosphate Dehydrogenase (G6PD) Defi-
ciency. Whole-blood samples from Madang and New Ireland
were screened for G6PD deficiency by using Sigma Procedure
no. 400 (Sigma).
Statistical Analysis. Statistical tests for differences in RBC CR1
levels between populations, between CR1 genotypes, and between
-thalassemia genotypes were performed by using multiway
ANOVA and F tests in the statistical package SAS (SAS Institute,
Cary, NC). Further analyses were performed to test for population
differences in the frequencies of the CR1 alleles and -thalassemia
genotype by using the2 test or Fisher’s exact test when the numbers
of observations per cell were small. Odds ratios for the protective
effects of genotypes in the case-control study were derived by
logistic regression analysis in SAS. Data were analyzed by using both
conditional and unconditional logistic regression; conditional lo-
gistic regression allows for matching of case-control pairs and
maximizes power. However, because CR1 genotyping was not
carried out in pairs, information was unnecessarily lost by using
conditional logistic regression, and so results from unconditional
analyses were used. This choice made no difference in the outcome
of the analysis, nor did the fitting of ethnic groups in the model
make a difference in the outcome.
Results
We measured the RBC CR1 levels of healthy adult volunteers
from two highly malarious regions of PNG (Madang and New
Ireland) and from a control Caucasian population from Ed-
inburgh, United Kingdom. CR1 levels in Edinburgh varied
between individuals in the range of 235–1,181 molecules per
cell, with a mean of 786 (Fig. 1a). These results are similar to
CR1 levels described in other Caucasian populations (Table 1),
showing that our assay for CR1 (24) is similar to those used
previously. In PNG, CR1 levels were significantly lower than
in Edinburgh (Fig. 1a, P  0.001), with 79% of individuals in
Madang and 55% of individuals in New Ireland having fewer
than 200 CR1 molecules per cell. The mean RBC CR1 levels
in Madang and New Ireland are the lowest in the world (Table
1). These results indicate that, in malarious regions of PNG,
CR1 deficiency is extremely common and could therefore play
a major role in inf luencing susceptibility to severe malaria.
To ascertain whether RBC CR1 levels in Melanesians are
genetically determined, we studied the three SNPs in the CR1
gene that have been associated with CR1 expression levels in
Caucasians (22). The CR1 exon 22 SNP (AG at nucleotide
3650) showed the strongest association with RBC CR1 level in
all three populations; therefore, only exon 22 data are shown. At
all three study sites the exon 22 genotype had a highly significant
effect on RBC CR1 level, with carriers of the G3650 low (L)
expression allele having significantly lower CR1 levels than HH
individuals (Fig. 1 b–d, F2,96  50, P  0.001). The RBC CR1
levels of HL individuals were intermediate between those of HH
and LL individuals, as expected for codominant alleles. The
frequency of the CR1 L allele in the malarious regions of PNG
is the highest described in the world to date (Table 1, significantly
different to Edinburgh, 26, P 0.01). DNA samples were also
studied from the nonmalarious Eastern Highlands Province of
PNG, and the frequency of the L allele was found to be
significantly lower than in the malarious regions (Table 1, 2 
8.1, P 0.01). This may indicate selection for the L allele in areas
with high malaria mortality, although other explanations cannot
be excluded. The data above indicate that RBC CR1 levels in
Melanesians are associated with polymorphisms in the CR1
gene. However, even when matched for exon 22 genotype, CR1
expression levels in Edinburgh, Madang, and New Ireland
remained significantly different from each other (F2,96  66.0,
P 0.001). For example, the CR1 levels of HH individuals from
PNG are lower than those of HH individuals from Edinburgh
(Fig. 1 b–d), suggesting that additional factors influence CR1
levels in Melanesians.
We investigated whether other RBC polymorphisms that
occur commonly in PNG such as ovalocytosis (30), G6PD
deficiency (32), and -thalassemia (32) could affect RBC CR1
levels. -Thalassemia occurred in 89% of individuals in
Madang and in 23% of individuals in New Ireland. At both
sites, individuals with one or more -thalassemia mutations
had RBC CR1 levels significantly lower than those of non-
thalassemic individuals (Fig. 2 a and b, F1,111  12.4, P 
0.001). The effect of -thalassemia genotype on RBC CR1
level was independent of the CR1 exon 22 polymorphism,
because both genotypes were statistically significant when
simultaneously included in the analysis (F2,110  10, P  0.001
for -thalassemia genotype; F2,110  44, P  0.001 for exon 22
genotype). Thus, an individual’s RBC CR1 level depends on
both their CR1 exon 22 genotype and their -globin genotype
(Fig. 2c). Significant population differences still remained
after including -thalassemia and CR1 exon 22 genotype in the
statistical model, suggesting that additional factors that inf lu-
ence RBC CR1 levels in Melanesians are undetected. Ovalo-
cytosis and G6PD deficiency occurred in up to 15% of
individuals in Madang and New Ireland and were not associ-
ated with RBC CR1 level (ovalocytosis, F1,115  0.2, P  0.10;
G6PD deficiency, F1,115  1.8, P  0.10).
To determine whether the low CR1 levels in PNG influence
susceptibility to severe malaria, we studied DNA samples from a
case-control study carried out in Madang. These samples have been
used previously to show that -thalassemia and ovalocytosis confer
protection against severe malaria (29, 30). One hundred eighty
severe malaria cases and 179 community controls (matched for age,
sex, ethnicity, season, and residential location) were genotyped for
the CR1 exon 22 polymorphism. The data were analyzed by logistic
regression, incorporating the previously identified protective fac-
tors of ovalocytosis (30) and -thalassemia (29) into the model. We
found that HL individuals for the CR1 exon 22 polymorphism were
significantly protected against severe malaria (odds ratio, 0.33; P
0.01; Table 2). The protective effect of the HL genotype was most
prominent when present on a homozygous -thalassemia back-
ground (odds ratio, 0.13; 95% confidence intervals, 0.02–0.67; P
0.005). In contrast, HHnormal -globin individuals, who would be
expected to have the highest CR1 levels (Figs. 1 and 2), were most
at risk of severe malaria, with this genotype being found in seven











severe cases but no controls (P 0.015 by Fisher’s exact test). When
the cases were subdivided into different severe malaria syndromes,
the odds ratios for the HL genotype were reduced for severe anemia
and cerebral malaria but not for other forms of severe malaria
(a pool of metabolic complications, Table 2). The odds ratios for the
LL genotype were also reduced for all severe malaria cases, severe
anemia, and cerebral malaria but did not reach statistical signifi-
cance (Table 2).
Fig. 1. RBC CR1 deficiency is common in Melanesians and is associated with SNPs in the CR1 gene. (a) RBC CR1 levels in Edinburgh (United Kingdom), Madang
(PNG), and New Ireland (PNG). Each point represents the mean RBC CR1 level of a single individual in molecules per cell. SD, standard deviation. (b–d) RBC CR1
levels in relation to CR1 genotype based on typing at the n3650 polymorphism in exon 22. H, high-expression allele; L, low-expression allele; na, not applicable.
Table 1. RBC CR1 levels and frequency of the CR1 low-expression (L) allele in different populations
Population No. tested
Mean RBC CR1 in molecules
per cell (range)
Gene frequency of
the CR1 L allele Ref.
Edinburgh, U.K. 31 786 (235–1181) 0.23 This study
New Ireland (PNG)* 47 253 (40–839) 0.73 This study
Madang (PNG)* 96 124 (0–439) 0.60 This study
Eastern Highlands Province (PNG)† 17 ND 0.41 This study
United Kingdom 60 624 (119–1220) 0.27 16
France 84 613 (161–712) 0.21 17
African Americans 54 635 (158–1023) 0.25 19
Caucasian Americans 53 547 (89–1166) 0.25 19
India 48 648 (140–1294) 0.23 18
Mali 149 415 (58–1032) 0.14 21
China 100 446 (27–1039) 0.28 20
Thailand 30 ND 0.52 36
The L allele is associated with low RBC CR1 levels in all populations studied to date, except for Africans or African Americans (19, 21).
ND, not determined.
*Sites in PNG with intense malaria transmission.
†Site in PNG with no regular malaria transmission.
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Discussion
This study shows that RBC CR1 deficiency is extremely common
in malaria-endemic regions of PNG and that polymorphisms
associated with CR1 deficiency confer protection against severe
malaria. As parasites invade and grow normally in both CR1-
deficient normal (33) and thalassemic RBCs (34), the simplest
interpretation of our findings is that these polymorphisms pro-
tect against severe malaria through CR1 deficiency bringing
about reduced rosetting (11, 35). Positive selection of rosette-
reducing polymorphisms in a human population with high
malaria mortality is strong evidence that CR1-mediated roset-
ting plays a causal role in the pathogenesis of severe malaria.
The case-control study results shown here indicate that het-
erozygotes for the CR1 low-expression allele (HL) are signifi-
cantly protected from severe malaria, whereas homozygotes
(LL) have a reduced odds ratio, but this reduction does not reach
statistical significance. It is unclear whether the difference
between the levels of protection provided by the HL and LL
genotypes is genuine, and a larger sample size would be required
to resolve this issue. The only previous small study of CR1
polymorphisms and malaria suggested that the LL genotype is a
risk factor for severe malaria in Thai adults (36). In Southeast
Asia, severe malaria in characterized mainly by metabolic dis-
turbances and multiorgan failure (37) rather than by severe
anemia and cerebral malaria, which occur commonly in children
Fig. 2. RBC CR1 deficiency in Melanesians is associated with-thalassemia. (a and b) RBC CR1 level in relation to-thalassemia genotype. Thalassemia genotypes
are the following:, heterozygotes for the4.2 deletion (32);, homozygotes for the4.2 deletion; and , normal -globin gene structure.
Only one individual carried the3.7 deletion (32); therefore, this case was excluded from the analysis. (c) The effect of -thalassemia and CR1 exon 22 genotype
on RBC CR1 level are independent of each other. The mean CR1 level for the Madang population subdivided by CR1 genotype (n3650 polymorphism) and
-thalassemia (4.2 deletion) is shown, and standard errors are indicated. The HHnormal -globin genotype was not represented.







(95% CI)* P value
All severe cases
n  180 n  178
HH 21 (12) 9 (5) 1
HL 57 (32) 81 (46) 0.33 (0.14–0.77) 0.01
LL 102 (56) 88 (49) 0.55 (0.24–1.28) 0.16
Severe anemia
n  113 n  109
HH 15 (13) 5 (5) 1
HL 34 (30) 45 (41) 0.30 (0.10–0.93) 0.04
LL 64 (57) 59 (54) 0.46 (0.15–1.40) 0.17
Cerebral malaria
n  45 n  46
HH 4 (9) 2 (4) 1
HL 15 (33) 21 (46) 0.40 (0.06–2.50) 0.33
LL 26 (58) 23 (50) 0.60 (0.10–3.69) 0.55
Other severe malaria†
n  58 n  58
HH 5 (9) 6 (10) 1
HL 18 (31) 25 (43) 1.18 (0.29–4.79) 0.82
LL 35 (60) 27 (47) 2.23 (0.56–8.87) 0.26
*Odds ratios for the HL and LL genotypes are calculated in relation to the HH genotype after adjusting for the
potential confounding factors ovalocytosis and -thalassemia. CI, confidence intervals.
†Hypoglycemia, acidosis (low plasma bicarbonate), and hyperlactatemia; the odds ratios were similar for all three
syndromes when analyzed separately.











in PNG (38). Our data for the small subgroup of children with
metabolic forms of severe malaria indicated a trend toward
increased risk for LL individuals. It is possible that the L allele
protects against the forms of severe malaria caused by micro-
vascular obstruction and RBC damage (by means of reduced
rosetting), but it increases risk for other syndromes with different
pathological mechanisms, such as multiorgan failure and meta-
bolic disturbances (39).
The results shown here linking RBC CR1 expression to
-thalassemia are striking. Although the protective effect of this
disorder is well known (25, 29), the mechanism is debated (40).
Parasite growth is unimpaired in thalassemic cells (34), so
investigators have sought explanations based on reduced cytoad-
herence (41) or enhanced immune recognition (42). Carlson et
al. (35) showed a large reduction in rosetting with thalassemic
RBCs. They argued that this could be a result of microcytosis,
because thalassemic cells have 15% less surface area than
normal RBCs (42). However, thalassemic RBCs formed rosettes
less well than microcytic RBCs with normal hemoglobin (35).
Microcytosis is insufficient to explain the reduction in RBC CR1,
which is 50% lower in thalassemic individuals than in those
with normal -globin (Fig. 2c). The mechanism responsible for
low CR1 on thalassemic RBCs is unclear. CR1 is preferentially
lost in vesicles from the cell surface as RBCs age or become
ATP-depleted (43, 44). It is possible that biochemical abnor-
malities in thalassemic RBCs promote a similar process that
would reduce their CR1 level.
The high prevalence of CR1 deficiency in Southeast Asia and
PNG could explain why rosetting is not associated with malaria
severity in this region (8, 9). Rosetting is greatly reduced in
CR1-deficient RBCs, but some small rosettes still form in in vitro
cultures, presumably by using other RBC receptors such as the
A or B blood group sugars (45). These small and weak rosettes
are unlikely to withstand the sheer forces encountered in the
circulation in vivo. Therefore, many of the rosettes observed in
vitro in Southeast Asia and PNG may not be physiologically
relevant. In Africa, on the other hand, RBC CR1 deficiency does
not appear to have been selected to high frequencies (19, 21).
Instead, African populations possess other CR1 polymorphisms,
such as the Knops blood group antigens that reach high fre-
quencies in East and West Africa (ref. 46 and J.A.R. and J.M.M.,
unpublished data). Our initial DNA-based studies of these
African CR1 polymorphisms have been complicated by a high
level of genotypephenotype mismatch (47); therefore, a pro-
spective case-control study is underway to examine the effect of
RBC CR1 phenotype on severe malaria in Africans. Clearly, the
selective pressure of malaria has acted in different ways on the
CR1 gene in diverse populations.
The results of this study have therapeutic implications. Case
fatality rates for severe malaria are high, even in areas with
intensive care facilities, so new approaches to treatment are
urgently needed (48). Our findings indicate that therapies aimed
at inhibiting CR1-mediated rosetting, such as soluble recombi-
nant CR1 (49), could be of benefit in treating severe malaria.
Alternatively, development of a vaccine against the parasite
rosette-mediating ligand PfEMP1 (11) may prevent some cases
of severe disease. The selective pressure of malaria on a major
rosetting receptor indicated by our results strongly supports a
direct role for CR1-mediated rosetting in the pathogenesis of
severe disease and emphasizes that further research to develop
rosette-inhibiting interventions should be a high priority.
We thank all the volunteers for donating blood for the study, Dr. E.
Mackinnon for the collection of blood samples from New Ireland, and
Professor David Weatherall and Professor John Clegg for permission to
use the case-control samples. This work was funded by Wellcome Trust
Grants 055167 and 067431 and by the United Kingdom Medical Re-
search Council.
1. Breman, J. G. (2001) Am. J. Trop. Med. Hyg. 64, 1–11.
2. David, P. H., Handunnetti, S. M., Leech, J. H., Gamage, P. & Mendis, K. N.
(1988) Am. J. Trop. Med. Hyg. 38, 289–297.
3. Kaul, D. K., Roth, E. F. J., Nagel, R. L., Howard, R. J. & Handunnetti, S. M.
(1991) Blood 78, 812–819.
4. Nash, G. B., Cooke, B. M., Carlson, J. & Wahlgren, M. (1992) Br. J. Haematol.
82, 757–763.
5. Carlson, J., Helmby, H., Hill, A. V., Brewster, D., Greenwood, B. M. &
Wahlgren, M. (1990) Lancet 336, 1457–1460.
6. Rowe, A., Obeiro, J., Newbold, C. I. & Marsh, K. (1995) Infect. Immun. 63,
2323–2326.
7. Ringwald, P., Peyron, F., Lepers, J. P., Rabarison, P., Rakotomalala, C.,
Razanamparany, M., Rabodonirina, M., Roux, J. & Le Bras, J. (1993) Infect.
Immun. 61, 5198–5204.
8. Ho, M., Davis, T. M., Silamut, K., Bunnag, D. & White, N. J. (1991) Infect.
Immun. 59, 2135–2139.
9. al-Yaman, F., Genton, B., Mokela, D., Raiko, A., Kati, S., Rogerson, S.,
Reeder, J. & Alpers, M. (1995) Trans. R. Soc. Trop. Med. Hyg. 89, 55–58.
10. Miller, L. H., Baruch, D. I., Marsh, K. & Doumbo, O. K. (2002) Nature 415,
673–679.
11. Rowe, J. A., Moulds, J. M., Newbold, C. I. & Miller, L. H. (1997) Nature 388,
292–295.
12. Chen, Q., Barragan, A., Fernandez, V., Sundstrom, A., Schlichtherle, M.,
Sahlen, A., Carlson, J., Datta, S. & Wahlgren, M. (1998) J. Exp. Med. 187,
15–23.
13. Rowe, J. A., Rogerson, S. J., Raza, A., Moulds, J. M., Kazatchkine, M. D.,
Marsh, K., Newbold, C. I., Atkinson, J. P. & Miller, L. H. (2000) J. Immunol.
165, 6341–6346.
14. Ahearn, J. M. & Fearon, D. T. (1989) Adv. Immunol. 46, 183–219.
15. Wilson, J. G., Murphy, E. E., Wong, W. W., Klickstein, L. B., Weis, J. H. &
Feardon, D. T. (1986) J. Exp. Med. 164, 50–59.
16. Moldenhauer, F., David, J., Fielder, A. H., Lachmann, P. J. & Walport, M. J.
(1987) Arthritis Rheum. 30, 961–966.
17. Cohen, J. H., Caudwell, V., Levi-Strauss, M., Bourgeois, P. & Kazatchkine,
M. D. (1989) Arthritis Rheum. 32, 393–397.
18. Kumar, A., Kumar, A., Sinha, S., Khandekar, P. S., Banerjee, K. & Srivastava,
L. M. (1995) Immunol. Cell Biol. 73, 457–462.
19. Herrera, A. H., Xiang, L., Martin, S. G., Lewis, J. & Wilson, J. G. (1998) Clin.
Immunol. Immunopathol. 87, 176–183.
20. Moulds, J. M., Brai, M., Cohen, J., Cortelazzo, A., Cuccia, M., Lin, M.,
Sadallah, S., Schifferli, J., Bala Subramanian, V., Truedsson, L., et al. (1998)
Exp. Clin. Immunogenet. 15, 291–294.
21. Rowe, J. A., Raza, A., Diallo, D. A., Baby, M., Poudiougo, B., Coulibaly, D.,
Cockburn, I. A., Middleton, J., Lyke, K. E., Plowe, C. V., et al. (2002) Genes
Immun. 3, 497–500.
22. Xiang, L., Rundles, J. R., Hamilton, D. R. & Wilson, J. G. (1999) J. Immunol.
163, 4939–4945.
23. Molthan, L. (1983) Med. Lab. Sci. 40, 59–63.
24. Cockburn, I. A., Donvito, B., Cohen, J. H. & Rowe, J. A. (2002) J. Immunol.
Methods 271, 59–64.
25. Flint, J., Hill, A. V., Bowden, D. K., Oppenheimer, S. J., Sill, P. R., Serjeantson,
S. W., Bana, K. J., Bhatia, K., Alpers, M. P., Boyce, A. J., et al. (1986) Nature
321, 744–750.
26. Cattani, J. A., Tulloch, J. L., Vrbova, H., Jolley, D., Gibson, F. D., Moir, J. S.,
Heywood, P. F., Alpers, M. P., Stevenson, A. & Clancy, R. (1986) Am. J. Trop.
Med. Hyg. 35, 3–15.
27. Chong, S. S., Boehm, C. D., Higgs, D. R. & Cutting, G. R. (2000) Blood 95,
360–362.
28. Jarolim, P., Palek, J., Amato, D., Hassan, K., Sapak, P., Nurse, G. T., Rubin,
H. L., Zhai, S., Sahr, K. E. & Liu, S. C. (1991) Proc. Natl. Acad. Sci. USA 88,
11022–11026.
29. Allen, S. J., O’Donnell, A., Alexander, N. D., Alpers, M. P., Peto, T. E., Clegg,
J. B. & Weatherall, D. J. (1997) Proc. Natl. Acad. Sci. USA 94, 14736–14741.
30. Allen, S. J., O’Donnell, A., Alexander, N. D., Mgone, C. S., Peto, T. E., Clegg,
J. B., Alpers, M. P. & Weatherall, D. J. (1999) Am. J. Trop. Med. Hyg. 60,
1056–1060.
31. Zhang, L., Cui, X., Schmitt, K., Hubert, R., Navidi, W. & Arnheim, N. (1992)
Proc. Natl. Acad. Sci. USA 89, 5847–5851.
32. Yenchitsomanus, P., Summers, K. M., Chockkalingam, C. & Board, P. G.
(1986) PNG Med. J. 29, 53–58.
33. Soubes, S. C., Reid, M. E., Kaneko, O. & Miller, L. H. (1999) Vox Sang 76,
107–114.
34. Luzzi, G. A., Torii, M., Aikawa, M. & Pasvol, G. (1990) Br. J. Haematol. 74,
519–524.
276  www.pnas.orgcgidoi10.1073pnas.0305306101 Cockburn et al.
35. Carlson, J., Nash, G. B., Gabutti, V., al-Yaman, F. & Wahlgren, M. (1994)
Blood 84, 3909–3914.
36. Nagayasu, E., Ito, M., Akaki, M., Nakano, Y., Kimura, M., Looareesuwan, S.
& Aikawa, M. (2001) Am. J. Trop. Med. Hyg. 64, 1–5.
37. White, N. J. (1987) Acta Leidensia 56, 27–47.
38. Allen, S. J., O’Donnell, A., Alexander, N. D. & Clegg, J. B., (1996) QJM 89,
779–788.
39. Warrell, D. A. (1987) Parasitology 94, S53–S76.
40. Weatherall, D. J., Miller, L. H., Baruch, D. I., Marsh, K., Doumbo, O. K.,
Casals-Pascual, C. & Roberts, D. J. (2002) Hematology (Am. Soc. Hematol.
Educ. Program) 1, 35–57.
41. Udomsangpetch, R., Sueblinvong, T., Pattanapanyasat, K., Dharmkrong-at, A.,
Kittikalayawong, A. & Webster, H. K. (1993) Blood 82, 3752–3759.
42. Luzzi, G. A., Merry, A. H., Newbold, C. I., Marsh, K., Pasvol, G. & Weatherall,
D. J. (1991) J. Exp. Med. 173, 785–792.
43. Pascual, M., Lutz, H. U., Steiger, G., Stammler, P. & Schifferli, J. A. (1993)
J. Immunol. 151, 397–404.
44. Dervillez, X., Oudin, S., Libyh, M. T., Tabary, T., Reveil, B., Philbert, F.,
Bougy, F., Pluot, M. & Cohen, J. H. (1997) Immunopharmacology 38,
129–140.
45. Carlson, J. & Wahlgren, M. (1992) J. Exp. Med. 176, 1311–1317.
46. Moulds, J. M., Kassambara, L., Middleton, J. J., Baby, M., Sagara, I., Guindo,
A., Coulibaly, S., Yalcouye, D., Diallo, D. A., Miller, L. & Doumbo, O. (2000)
Genes Immun. 1, 325–329.
47. Zimmerman, P. A., Fitness, J., Moulds, J. M., McNamara, D. T., Kasehagen,
L. J., Rowe, J. A. & Hill, A. V. S. (2003) Genes Immun. 4, 368–373.
48. Warrell, D., A. (1999) Parassitologia (Rome) 41, 287–294.
49. Weisman, H. F., Bartow, T., Leppo, M. K., Marsh, H. C., Carson, G. R.,
Concino, M. F., Boyle, M. P., Roux, K. H., Weisfeldt, M. L. & Fearon, D. T.
(1990) Science 249, 146–151.
Cockburn et al. PNAS  January 6, 2004  vol. 101  no. 1  277
M
ED
IC
A
L
SC
IE
N
CE
S
